AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6882615 — intervention group
Group type: COMPARATOR
Intervention: Aqueous preparation (Valium)
Number of subjects: 100
Study 6882615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 100
Study 30963440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Improvement through Food and Exercise (LIFE), a culturally tailored, 28-session community-based intervention focused on diet and physical activity
Number of subjects: 211
Study 30963440 — intervention group
Group type: COMPARATOR
Intervention: Standard of care comparison group receiving two group DSME classes
Number of subjects: 211
Study 30963440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Improvement through Food and Exercise (LIFE)
Number of subjects: 211
Study 30963440 — intervention group
Group type: COMPARATOR
Intervention: Standard of care comparison group
Number of subjects: 211
Study 29568979 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle (Contiplex C™)
Number of subjects: 40
Study 29568979 — intervention group
Group type: COMPARATOR
Intervention: Catheter-through-needle (Contiplex Touhy™)
Number of subjects: 40
Study 27483064 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/d via daily subcutaneous injection for 180 days)
Number of subjects: 300
Study 27483064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 27483064 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 300
Study 25197833 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction
Number of subjects: 4321
Study 25197833 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction in hypoperfusion-dominant profiles
Number of subjects: 4321
Study 25197833 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction in congestion-dominant profiles
Number of subjects: 4321
Study 22892437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet
Number of subjects: 84
Study 22892437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) test breakfast
Number of subjects: 84
Study 19604249 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 25
Study 19604249 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 25
Study 17470860 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 244
Study 17470860 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 244
Study 15175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial vitamin C (25 mg/min)
Number of subjects: 8
Study 15175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C (1 g daily)
Number of subjects: 8
Study 15175566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 8
Study 10838017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (multiple dose oral administration every 12 h, eight active dosing levels)
Number of subjects: 78
Study 10838017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 78
Study 9327310 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming devices
Number of subjects: 60
Study 9327310 — intervention group
Group type: COMPARATOR
Intervention: Usual patient care (warm blankets and overhead heat lamps)
Number of subjects: 60
Study 8261939 — intervention group
Group type: COMPARATOR
Intervention: Garcinia Kola (15 grammes per subject)
Number of subjects: 19
Study 3766413 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (IS 5‐MN), 40 mg twice daily
Number of subjects: 18
Study 3766413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3399285 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous gamma-globulin (0.6 g/kg every 4 weeks)
Number of subjects: 0
Study 3399285 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous gamma-globulin
Number of subjects: 0
Study 3399285 — intervention group
Group type: COMPARATOR
Intervention: Low dose therapy (not specified in detail)
Number of subjects: 0
Study 31971616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured closure of the fascial defect before intraperitoneal onlay mesh (IPOM) repair
Number of subjects: 80
Study 31971616 — intervention group
Group type: COMPARATOR
Intervention: No closure of the fascial defect before intraperitoneal onlay mesh (IPOM) repair
Number of subjects: 80
Study 31642434 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-enriched formula milk powder (100 kcal/100 mL)
Number of subjects: 43
Study 31642434 — intervention group
Group type: COMPARATOR
Intervention: Normal calorie formula milk powder (67 kcal/100 mL)
Number of subjects: 43
Study 28619777 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate disc (CHG)
Number of subjects: 1240
Study 28619777 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated securement dressing (ISD)
Number of subjects: 1240
Study 28619777 — intervention group
Group type: COMPARATOR
Intervention: Securement device (SED)
Number of subjects: 1240
Study 28619777 — intervention group
Group type: COMPARATOR
Intervention: No disc (control for dressing hypothesis)
Number of subjects: 1240
Study 25649018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 175
Study 25649018 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 175
Study 24009294 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SPR) added to ARB
Number of subjects: 136
Study 24009294 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors and ARBs (continuation regimen)
Number of subjects: 136
Study 21782524 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 220
Study 21782524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 17851675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensor veli palatini muscle function analysis using electromyography (EMG)
Number of subjects: 24
Study 17851675 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 24
Study 16960401 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH)
Number of subjects: 0
Study 16960401 — intervention group
Group type: COMPARATOR
Intervention: Traditional TSH stimulation (hypothyroidism induction)
Number of subjects: 0
Study 14761120 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ/pulse, 10 Hz) plus enamel matrix protein derivative (EMD)
Number of subjects: 22
Study 14761120 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) with hand instruments plus EDTA and EMD
Number of subjects: 22
Study 10708085 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior capsulorrhaphy (group 1, 96 cases)
Number of subjects: 180
Study 10708085 — intervention group
Group type: COMPARATOR
Intervention: No posterior capsulorrhaphy (group 2, 84 cases)
Number of subjects: 180
Study 9575601 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide, 300 mg t.i.d.
Number of subjects: 50
Study 9575601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7902022 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 95
Study 7902022 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 95
Study 7902022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 3709210 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% fenticonazole cream
Number of subjects: 60
Study 3709210 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% miconazole cream
Number of subjects: 60
Study 30477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy applied through individual sessions for 8 weeks, with house visits once a week.
Number of subjects: 50
Study 30477828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 50
Study 25564998 — intervention group
Group type: EXPERIMENTAL
Intervention: PO (5 min prior to exercise)
Number of subjects: 0
Study 25564998 — intervention group
Group type: EXPERIMENTAL
Intervention: IO (immediately prior to exercise)
Number of subjects: 0
Study 25564998 — intervention group
Group type: COMPARATOR
Intervention: CON (no occlusion during exercise)
Number of subjects: 0
Study 24330860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 486
Study 24330860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/d
Number of subjects: 486
Study 24330860 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg/d
Number of subjects: 486
Study 24330860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 22544016 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg (started at 10 mg/d, increased to 20 mg/d after 4 weeks)
Number of subjects: 40
Study 22544016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22544016 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 40
Study 20635355 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine and folic acid
Number of subjects: 48
Study 20635355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 48
Study 18717089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti-15% Zr alloy crowns
Number of subjects: 20
Study 18717089 — intervention group
Group type: COMPARATOR
Intervention: Gold-palladium alloy crowns
Number of subjects: 20
Study 18717089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both crowns
Number of subjects: 20
Study 15997019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 122
Study 15997019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride
Number of subjects: 122
Study 15997019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behavioral therapy and fluoxetine hydrochloride
Number of subjects: 122
Study 15997019 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 122
Study 15997019 — intervention group
Group type: COMPARATOR
Intervention: Overall dropout rate
Number of subjects: 122
Study 12622581 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy (coronary angiography followed by revascularization if feasible)
Number of subjects: 282
Study 12622581 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical therapy
Number of subjects: 282
Study 11138536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea ointment
Number of subjects: 104
Study 11138536 — intervention group
Group type: COMPARATOR
Intervention: Soframycin (Framycetin and gramicidin)
Number of subjects: 104
Study 11138536 — intervention group
Group type: COMPARATOR
Intervention: Oral cephalexin
Number of subjects: 104
Study 9178345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (once a week for a total of four sessions)
Number of subjects: 30
Study 9178345 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback treatment (after self-monitoring control period)
Number of subjects: 30
Study 9178345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 30
Study 8472155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 24
Study 8472155 — intervention group
Group type: COMPARATOR
Intervention: No pyloroplasty
Number of subjects: 24
Study 3620275 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam, 200 mg once daily
Number of subjects: 19
Study 3620275 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen, 100 mg three times daily
Number of subjects: 19
Study 29783899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 47
Study 29783899 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercise
Number of subjects: 47
Study 29783899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 28333990 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention programme applied by teachers to support autonomy, competence, and relatedness.
Number of subjects: 921
Study 28333990 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 921
Study 25005017 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (running on a treadmill for 20 min at 60% of VO2 max)
Number of subjects: 52
Study 25005017 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated work for 40 min, then practicing peg transfer and pattern cut for 10 min, and intracorporeal suture for 15 min)
Number of subjects: 52
Study 23298972 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 544
Study 23298972 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 544
Study 23298972 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus iron-folic acid supplementation
Number of subjects: 544
Study 23298972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 22903851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (therapists and patients reviewed their respective ratings)
Number of subjects: 16
Study 22903851 — intervention group
Group type: COMPARATOR
Intervention: Control condition (ratings given directly to the investigator without review)
Number of subjects: 16
Study 18311688 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (0.4 mg/kg body weight, mean 31.96±4.45 mg)
Number of subjects: 23
Study 18311688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18311688 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 23
Study 16610924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed care (DMCP)
Number of subjects: 367
Study 16610924 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 367
Study 12972469 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hip OA
Number of subjects: 508
Study 12972469 — intervention group
Group type: COMPARATOR
Intervention: Men with hip OA
Number of subjects: 508
Study 10476017 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of medical students during appointments
Number of subjects: 325
Study 10476017 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent alone with the doctor
Number of subjects: 325
Study 10476017 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre B (longer appointments with students)
Number of subjects: 325
Study 10476017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower social classes and older patients
Number of subjects: 325
Study 10476017 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of students
Number of subjects: 325
Study 9084545 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 30 mg i.v.
Number of subjects: 30
Study 9084545 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 0.5 g/kg i.v.
Number of subjects: 30
Study 1651994 — intervention group
Group type: COMPARATOR
Intervention: VP‐16 (etoposide)
Number of subjects: 94
Study 1651994 — intervention group
Group type: EXPERIMENTAL
Intervention: VM‐26 (teniposide)
Number of subjects: 94
Study 7058448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tube
Number of subjects: 0
Study 7058448 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of investigation
Number of subjects: 0
Study 30822621 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 + Sorafenib 400 mg bid
Number of subjects: 102
Study 30822621 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m2 + Placebo
Number of subjects: 102
Study 28946838 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5 ml GO-ON injection
Number of subjects: 127
Study 28946838 — intervention group
Group type: COMPARATOR
Intervention: Conventional three injections of 2.5 ml GO-ON at weekly intervals
Number of subjects: 127
Study 25296729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite-Jumping Appliance (BJA)
Number of subjects: 40
Study 25296729 — intervention group
Group type: COMPARATOR
Intervention: Twin-Block Appliance (TBA)
Number of subjects: 40
Study 24456357 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria japonica with LAB
Number of subjects: 40
Study 24456357 — intervention group
Group type: COMPARATOR
Intervention: Laminaria japonica with placebo LAB
Number of subjects: 40
Study 22394648 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/formoterol (200 μg/12 μg)
Number of subjects: 0
Study 22394648 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/salbutamol (200 μg/200 μg)
Number of subjects: 0
Study 22394648 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 0
Study 19958918 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention programme (12 months duration)
Number of subjects: 591
Study 19958918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 591
Study 17537096 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review
Number of subjects: 452
Study 17537096 — intervention group
Group type: COMPARATOR
Intervention: No medication review
Number of subjects: 452
Study 15274752 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with antioxidants (vitamins C and E, beta-carotene, and selenium)
Number of subjects: 57
Study 15274752 — intervention group
Group type: COMPARATOR
Intervention: Methimazole only (Control group B)
Number of subjects: 57
Study 15274752 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with antioxidants
Number of subjects: 57
Study 11427243 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month collaborative care intervention provided by a trauma support specialist
Number of subjects: 34
Study 11427243 — intervention group
Group type: COMPARATOR
Intervention: Usual posttraumatic care (Control)
Number of subjects: 34
Study 9701099 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day triple therapy (30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 14 days)
Number of subjects: 236
Study 9701099 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day triple therapy (30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 days)
Number of subjects: 236
Study 9701099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to therapy in 14-day group
Number of subjects: 236
Study 9701099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to therapy in 10-day group
Number of subjects: 236
Study 7501140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 93
Study 7501140 — intervention group
Group type: COMPARATOR
Intervention: Pemoline
Number of subjects: 93
Study 7501140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 2224165 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2 alone or in combination with LAK cells, INF alpha or TNF
Number of subjects: 66
Study 2224165 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2 either alone or in combination with LAK cells
Number of subjects: 66
Study 2224165 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2
Number of subjects: 66
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy-radiotherapy (CT)
Number of subjects: 107
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy-radiotherapy with radiation to involved fields (CTIF)
Number of subjects: 107
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy-radiotherapy with total nodal radiation (CTTN)
Number of subjects: 107
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal radiation followed by chemotherapy (TNCT)
Number of subjects: 107
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal radiation (TN)
Number of subjects: 107
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation +/− chemotherapy
Number of subjects: 107
Study 445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 107
Study 31108227 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 31108227 — intervention group
Group type: COMPARATOR
Intervention: Golimumab
Number of subjects: 0
Study 31120533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 151
Study 31120533 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Tinnitus Retraining Therapy (Partial TRT)
Number of subjects: 151
Study 31120533 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 151
Study 28570216 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene
Number of subjects: 0
Study 28570216 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 0
Study 25927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (group A, n=35)
Number of subjects: 70
Study 25927657 — intervention group
Group type: COMPARATOR
Intervention: GlideScope (group G, n=35)
Number of subjects: 70
Study 25927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (group A)
Number of subjects: 70
Study 25927657 — intervention group
Group type: COMPARATOR
Intervention: GlideScope (group G)
Number of subjects: 70
Study 24015915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 1578
Study 24015915 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (Control)
Number of subjects: 1578
Study 21953205 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications for the treatment of fibromyalgia (specific medications not detailed)
Number of subjects: 12
Study 21953205 — intervention group
Group type: EXPERIMENTAL
Intervention: FM30 version 3 (short version)
Number of subjects: 12
Study 21953205 — intervention group
Group type: EXPERIMENTAL
Intervention: FM30 version 6 (long version)
Number of subjects: 12
Study 21953205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12